Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06378892
Title	A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL)
Acronym	ALK-PPL
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Centro di Riferimento Oncologico - Aviano
Indications	lung non-small cell carcinoma
Therapies	Cisplatin + Lorlatinib + Pemetrexed Disodium Carboplatin + Lorlatinib + Pemetrexed Disodium Lorlatinib + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	ITA